Breakthrough Urine Test Could Spare Patients Invasive Procedures

A novel at-home urine test, currently in NHS trials, has demonstrated the ability to detect over 90% of bladder cancer cases. Researchers are optimistic that this development could significantly decrease the number of patients requiring urgent and invasive cystoscopies. This diagnostic method analyzes genetic material shed into urine by bladder cancer cells, looking for over 450 specific DNA mutations across 23 genes. The study, involving nearly 1,000 patients across seven hospitals in England and Scotland, was led by the University of Birmingham and Nonacus. Professor Richard Bryan of Birmingham University expressed excitement about the test's promising early performance in a real-world patient setting. While not a complete replacement for cystoscopies, the urine test can help prioritize patients at higher risk who need immediate procedures. A negative result from this test provides a high degree of confidence that a patient does not have bladder cancer. Commercialized by Nonacus, the test aims to tackle the challenge of delayed bladder cancer diagnoses. Further research is underway to validate its effectiveness for wider clinical use.